Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC Reaffirms FY 2013 Guidance-Conference Call

Tuesday, 21 May 2013 09:30am EDT 

Jazz Pharmaceuticals PLC announced that for fiscal 2013, it expects revenues guidance to be in the range of $830 million up to $860 million and adjusted EPS guidance of $6.10 to $6.30. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $849 and EPS of $6.15 for fiscal 2013 

Company Quote

-2.05 -1.25%
17 Sep 2014